Andrea Del Fattore

List of Publications by Year
in descending order

63	4,393	159358 30	138251 58
papers	citations	h-index	g-index

64	64	64	6624
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Insulin Signaling in Osteoblasts Integrates Bone Remodeling and Energy Metabolism. Cell, 2010, 142, 296-308.	13.5	957
2	Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nature Genetics, 2007, 39, 960-962.	9.4	346
3	Impaired skeletal development in interleukin-6â€“transgenic mice: A model for the impact of chronic inflammation on the growing skeletal system. Arthritis and Rheumatism, 2006, 54, 3551-3563.	6.7	271
4	Genetics, pathogenesis and complications of osteopetrosis. Bone, 2008, 42, 19-29.	1.4	240
5	Immunoregulatory Effects of Mesenchymal Stem Cell-Derived Extracellular Vesicles on T Lymphocytes. Cell Transplantation, 2015, 24, 2615-2627.	1.2	228
6	Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nature Medicine, 2009, 15, 674-681.	15.2	172
7	Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. Journal of Medical Genetics, 2005, 43, 315-325.	1.5	164
8	Differential effects of extracellular vesicles secreted by mesenchymal stem cells from different sources on glioblastoma cells. Expert Opinion on Biological Therapy, 2015, 15, 495-504.	1.4	140
9	Inhibition of Protein Kinase c-Src Reduces the Incidence of Breast Cancer Metastases and Increases Survival in Mice: Implications for Therapy. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 161-172.	1.3	126
10	Mechanisms inducing low bone density in duchenne muscular dystrophy in mice and humans. Journal of Bone and Mineral Research, 2011, 26, 1891-1903.	3.1	116
11	Strategies for Bone Regeneration: From Graft to Tissue Engineering. International Journal of Molecular Sciences, 2021, 22, 1128.	1.8	106
12	c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling. Nature Communications, 2012, 3, 630.	5.8	93
13	Recent Advances in Mesenchymal Stem Cell Immunomodulation: The Role of Microvesicles. Cell Transplantation, 2015, 24, 133-149.	1.2	91
14	Osteoclast receptors and signaling. Archives of Biochemistry and Biophysics, 2008, 473, 147-160.	1.4	83
15	Osteopenia, decreased bone formation and impaired osteoblast development inSox4heterozygous mice. Journal of Cell Science, 2007, 120, 2785-2795.	1.2	80
16	The glycosaminoglycan-binding domain of PRELP acts as a cell typeâ€“specific NF-Îºß inhibitor that impairs osteoclastogenesis. Journal of Cell Biology, 2009, 187, 669-683.	2.3	72
17	Bone-Targeted Doxorubicin-Loaded Nanoparticles as a Tool for the Treatment of Skeletal Metastases. Current Cancer Drug Targets, 2010, 10, 649-659.	0.8	72
18	A New Heterozygous Mutation (R714C) of the Osteopetrosis Gene, Pleckstrin Homolog Domain Containing Family M (With Run Domain) Member 1 (PLEKHM1), Impairs Vesicular Acidification and Increases TRACP Secretion in Osteoclasts. Journal of Bone and Mineral Research, 2008, 23, 380-391.	3.1	69

#	Article	IF	Citations
19	Imaging of extracellular vesicles derived from human bone marrow mesenchymal stem cells using fluorescent and magnetic labels. International Journal of Nanomedicine, 2018, Volume 13, 1653-1664.	3.3	64
20	ZNF687 Mutations in Severe Paget Disease of Bone Associated with Giant Cell Tumor. American Journal of Human Genetics, 2016, 98, 275-286.	2.6	61
21	Receptor Activator of NF-Î°B Ligand Enhances Breast Cancerâ€“Induced Osteolytic Lesions through Upregulation of Extracellular Matrix Metalloproteinase Inducer/CD147. Cancer Research, 2010, 70, 6150-6160.	0.4	54
22	Bone cells and the mechanisms of bone remodelling. Frontiers in Bioscience - Elite, 2012, E4, 2302.	0.9	49
23	Osteopetrosis and Its Relevance for the Discovery of New Functions Associated with the Skeleton. International Journal of Endocrinology, 2015, 2015, 1-8.	0.6	49
24	Novel C16orf57 mutations in patients with Poikiloderma with Neutropenia: bioinformatic analysis of the protein and predicted effects of all reported mutations. Orphanet Journal of Rare Diseases, 2012, 7, 7.	1.2	48
25	The Role of Autophagy in Osteoclast Differentiation and Bone Resorption Function. Biomolecules, 2020, 10, 1398.	1.8	47
26	Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1685-1699.	1.2	40
27	CLCN7 and TCIRG1 Mutations Differentially Affect Bone Matrix Mineralization in Osteopetrotic Individuals. Journal of Bone and Mineral Research, 2014, 29, 982-991.	3.1	38
28	Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models. Bone, 2014, 59, 66-75.	1.4	36
29	The Role of Extracellular Vesicles in Bone Metastasis. International Journal of Molecular Sciences, 2018, 19, 1136.	1.8	35
30	The Immunoregulatory Activity of Mesenchymal Stem Cells: â€˜State of Artâ€™ and â€˜Future Avenuesâ€™. Current Medicinal Chemistry, 2016, 23, 3014-3024.	1.2	35
31	Bone Control of Muscle Function. International Journal of Molecular Sciences, 2020, 21, 1178.	1.8	32
32	Bone and bone marrow: The same organ. Archives of Biochemistry and Biophysics, 2010, 503, 28-34.	1.4	29
33	Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells. Journal of Hematology and Oncology, 2017, 10, 161.	6.9	29
34	The Endocrine Function of Osteocalcin Regulated by Bone Resorption: A Lesson from Reduced and Increased Bone Mass Diseases. International Journal of Molecular Sciences, 2019, 20, 4502.	1.8	29
35	NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance. Journal of Cancer Research and Clinical Oncology, 2019, 145, 881-893.	1.2	28
36	Dissecting the mechanisms of bone loss in Gorham-Stout disease. Bone, 2020, 130, 115068.	1.4	28

#	Article	IF	Citations
37	Percentiles of serum uric acid and cardiometabolic abnormalities in obese Italian children and adolescents. Italian Journal of Pediatrics, 2017, 43, 3.	1.0	25
38	The Tight Relationship Between Osteoclasts and the Immune System. Inflammation and Allergy: Drug Targets, 2012, 11, 181-187.	1.8	22
39	Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines. Cancer Letters, 2019, 461, 90-101.	3.2	22
40	Differentially expressed genes in autosomal dominant osteopetrosis type II osteoclasts reveal known and novel pathways for osteoclast biology. Laboratory Investigation, 2014, 94, 275-285.	1.7	20
41	Cellular and Molecular Mediators of Bone Metastatic Lesions. International Journal of Molecular Sciences, 2018, 19, 1709.	1.8	15
42	The Use of Mesenchymal Stem Cells for the Treatment of Autoimmunity: From Animals Models to Human Disease. Current Drug Targets, 2016, 17, 229-238.	1.0	15
43	Intrinsic Bone Defects in Cystinotic Mice. American Journal of Pathology, 2019, 189, 1053-1064.	1.9	14
44	Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?. International Journal of Molecular Sciences, 2021, 22, 12586.	1.8	12
45	Committed osteoclast precursors colonize the bone and improve the phenotype of a mouse model of autosomal recessive osteopetrosis. Journal of Bone and Mineral Research, 2010, 25, 106-113.	3.1	11
46	Dysregulated miRNAs in bone cells of patients with Gorhamâ€Stout disease. FASEB Journal, 2021, 35, e21424.	0.2	11
47	Bioprinting Technology in Skin, Heart, Pancreas and Cartilage Tissues: Progress and Challenges in Clinical Practice. International Journal of Environmental Research and Public Health, 2021, 18, 10806.	1.2	11
48	Skeletal abnormalities are common features in AymÃ©â€Gripp syndrome. Clinical Genetics, 2020, 97, 362-369.	1.0	10
49	An experimental therapy to improve skeletal growth and prevent bone loss in a mouse model overexpressing IL-6. Osteoporosis International, 2014, 25, 681-692.	1.3	8
50	New Perspectives in Glioblastoma: Nanoparticles-based Approaches. Current Cancer Drug Targets, 2017, 17, 203-220.	0.8	8
51	Dual PI3â€‰K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling. Tumor Biology, 2018, 40, 101042831877177.	0.8	7
52	New mechanisms of osteopetrosis. IBMS BoneKEy, 2009, 6, 16-28.	0.1	6
53	A 3D-Printed Multi-Chamber Device Allows Culturing Cells On Buckypapers Coated With PAMAM Dendrimer And Obtain Innovative Materials For Biomedical Applications . International Journal of Nanomedicine, 2019, Volume 14, 9295-9306.	3.3	5
54	Nanoparticles-Based Treatment for Bone Metastasis. Current Drug Targets, 2016, 17, 303-310.	1.0	5

#	Article	IF	Citations
55	Stimulation of Treg Cells to Inhibit Osteoclastogenesis in Gorham-Stout Disease. Frontiers in Cell and Developmental Biology, 2021, 9, 706596.	1.8	4
56	The Endocrine Role of the Skeleton. International Journal of Endocrinology, 2015, 2015, 1-2.	0.6	2
57	Editorial: Advances in the Endocrine Role of the Skeleton. Frontiers in Endocrinology, 2020, 11, 591085.	1.5	2
58	MECHANISMS INDUCING LOW BONE DENSITY IN DUCHENNE MUSCULAR DYSTROPHY. Bone, 2010, 46, S79-S80.	1.4	1
59	New Experimental Therapeutic Approach by siRNA for Autosomal Dominant Osteopetrosis (ADO). Bone, 2010, 46, S61.	1.4	0
60	The N-terminal domain of the bone protein PRoline/arginine-rich End Leucine-rich repeat Protein (PRELP) impairs osteoclast formation by a new mechanism inhibiting NF-kappaB signaling. Bone, 2010, 46, S64-S65.	1.4	0
61	Osteopetrosi: patogenesi, clinica e terapia. L Endocrinologo, 2011, 12, 232-238.	0.0	0
62	The glycosaminoglycan-binding domain of PRELP acts as a cell typeâ€“specific NF-kB inhibitor that impairs osteoclastogenesis. Journal of Experimental Medicine, 2009, 206, i32-i32.	4.2	0
63	Reusability of P3 Facial Filter in a Pandemic Emergency: A 3D Analysis of Filter Microstructure with X-ray Microtomography Images after Dry Heat and UV Sterilization Procedures. International Journal of Environmental Research and Public Health, 2022, 19, 3435.	1.2	0